Bloodstream infection in a neonatal intensive care unit: Epidemiology, Antifungal susceptibility and new drug delivered strategies

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2025-01-18 DOI:10.1016/j.mycmed.2025.101535

Matheus Ribeiro , Luciana da Silva Ruiz , Rinaldo Ferreira Gandra , Rubiana Mara Mainardes , Carine Teles Sangaleti Miyahara , Débora Moreira , Maurício Domingues-Ferreira , Diniz Pereira Leite Junior , Claudete Rodrigues Paula , Marcos Ereno Auler

{"title":"Bloodstream infection in a neonatal intensive care unit: Epidemiology, Antifungal susceptibility and new drug delivered strategies","authors":"Matheus Ribeiro , Luciana da Silva Ruiz , Rinaldo Ferreira Gandra , Rubiana Mara Mainardes , Carine Teles Sangaleti Miyahara , Débora Moreira , Maurício Domingues-Ferreira , Diniz Pereira Leite Junior , Claudete Rodrigues Paula , Marcos Ereno Auler","doi":"10.1016/j.mycmed.2025.101535","DOIUrl":null,"url":null,"abstract":"<div><div>Bloodstream infection in neonates is a complicated disease and presents a major challenge both in diagnosis and in therapeutic intervention. The focus of the present study was to investigate the incidence, the species distribution and the risk factors associated with mortality of bloodstream infections in a neonatal intensive care unit (NICU) and evaluating the antifungal susceptibility of traditional antifungal drugs and three nanoparticle-based drug delivery systems based on nanoparticles. A total of 458 patients were evaluated, and 9.38 % were confirmed to have bloodstream infections through laboratory tests. The death rate was higher among neonates with fungal infections (66.7 %) compared to those with bacterial infections (5.4 %). Severe health conditions contributed to the increased mortality rate, especially gestational age <em><</em>28 weeks and weight <em><</em>1.000 g. Coagulase-negative staphylococci were the major pathogens (64.9 %) considering cases of neonatal sepsis. <em>Candida albicans</em> was the predominant causative agent among neonates with fungemia, although non-<em>albicans</em> species led to the highest mortality rates. <em>In vitro</em> antifungal activity evidenced resistance of <em>C. tropicalis</em> to fluconazole and voriconazole. Three nanoparticles were evaluated: chitosan-coated PLGA containing Amphotericin B, zein containing voriconazole and PLA containing voriconazole, and results were considered promising. The present findings demonstrate the importance of constant epidemiological surveillance in a NICU and the severity of fungal infection in neonates. The results suggest the potential of nanotechnology as an alternative in the treatment of fungal infection.</div></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"35 1","pages":"Article 101535"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523325000046","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Bloodstream infection in neonates is a complicated disease and presents a major challenge both in diagnosis and in therapeutic intervention. The focus of the present study was to investigate the incidence, the species distribution and the risk factors associated with mortality of bloodstream infections in a neonatal intensive care unit (NICU) and evaluating the antifungal susceptibility of traditional antifungal drugs and three nanoparticle-based drug delivery systems based on nanoparticles. A total of 458 patients were evaluated, and 9.38 % were confirmed to have bloodstream infections through laboratory tests. The death rate was higher among neonates with fungal infections (66.7 %) compared to those with bacterial infections (5.4 %). Severe health conditions contributed to the increased mortality rate, especially gestational age <28 weeks and weight <1.000 g. Coagulase-negative staphylococci were the major pathogens (64.9 %) considering cases of neonatal sepsis. Candida albicans was the predominant causative agent among neonates with fungemia, although non-albicans species led to the highest mortality rates. In vitro antifungal activity evidenced resistance of C. tropicalis to fluconazole and voriconazole. Three nanoparticles were evaluated: chitosan-coated PLGA containing Amphotericin B, zein containing voriconazole and PLA containing voriconazole, and results were considered promising. The present findings demonstrate the importance of constant epidemiological surveillance in a NICU and the severity of fungal infection in neonates. The results suggest the potential of nanotechnology as an alternative in the treatment of fungal infection.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.